UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO___________ Commission File Number 001-39587 23ANDME HOLDING CO. (Exact name of Registrant as specified in its Charter) Delaware 87-1240344 (State or other jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

23andMe Holding Co. (NASDAQ:ME) Q2 2023 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Wade Walke - Vice President-Investor Relations Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim Chief Financial Officer & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Tiago Fauth - Credit Suisse Steven Mah - Cowen Operator Good day, and thank you for standing by. Welcome to the 23andMe's Fiscal Year 2023 Second Quarter E ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 23ANDME HOLDING CO. (Exact name of registrant as specified in its charter) Delaware 87-1240344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...

23andMe Holding Co. (NASDAQ:ME) Q1 2023 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Wade Walke - Vice President, Investor Relations Anne Wojcicki - Chief Executive Officer & Co-Founder Steve Schoch - Chief Financial Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Tiago Fauth - Credit Suisse David Lebowitz - Citi Operator Good morning, and welcome to 23andMe's Fiscal 2023 First Quarter Financial Results Conference Call. As a reminder this call is b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39587 23ANDME HOLDING CO. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

23andMe Holding Co. (NASDAQ:ME) Q4 2022 Earnings Conference Call May 26, 2022 4:30 PM ET Company Participants Wade Walke - Vice President of Investor Relations Anne Wojcicki - Co-Founder and Chief Executive Officer Kenneth Hillan - Chief Therapeutics Officer Steve Schoch - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse AG Daniel Grosslight - Citigroup Inc. Operator Good morning, and welcome to the 23andMe's Fiscal Year 2022 Fourth Quarter and Year-End Financial Results Conf ...

FORM 10-K Table of Contents (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO___________ Commission File Number 001-39587 23ANDME HOLDING CO. (Exact name of Registrant as specified in its Charter) Delaware 87-1240344 (State ...

23andMe Holding Co. (NASDAQ:ME) Q3 2022 Earnings Conference Call February 10, 2022 4:30 PM ET Company Participants Wade Walke - Vice President of Investor Relations Anne Wojcicki - Co-Founder & Chief Executive Officer Steve Schoch - Chief Financial Officer Kenneth Hillan - Head of Therapeutics Conference Call Participants Tiago Fauth - Credit Suisse Daniel Grosslight - Citi Operator Good morning and welcome to 23andMe's Fiscal Year 2022 Third Quarter Financial Results Conference Call. As a reminder, this ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39587 23ANDME HOLDING CO. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...